Compare 10X Genomics Inc (TXG) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard High Dividend Yield ETF — how do they compare? 10X Genomics Inc trades at $79.3 (market cap $9.92B), while Vanguard High Dividend Yield ETF trades at $158.5 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 10.2× 10X Genomics Inc's market cap, and Vanguard High Dividend Yield ETF is more actively traded (993,696 versus 9,372,166). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| TXG | VYM | |
|---|---|---|
Market Cap | $9.92B | $100.80B |
Volume | 9,372,166 | 993,696 |
Sector | Health | — |
52-Week High | $97.74 | $167.03 |
52-Week Low | $11.48 | $137.47 |
Typical Hold Time | 92 Days | 138 Days |
Enterprise Value | $9.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
VYM trades at $157.45, down 0.58% on the day, with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's 2.42% yield provides consistent income, though recent articles highlight performance comparisons with peers like SCHD and IDV. Support and resistance levels cluster tightly around $157-158, indicating potential for near-term price consolidation.
The outlook remains cautious as VYM faces competitive pressure from higher-yielding alternatives and concerns about dividend sustainability in its holdings. While diversification and low costs are strengths, investors should weigh the trade-offs between yield consistency and total return potential in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
